Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Assembly, Biochemical Characterization, Immunogenicity, Adjuvanticity, and Efficacy of Shigella Artificial Invaplex.

Turbyfill KR, Clarkson KA, Vortherms AR, Oaks EV, Kaminski RW.

mSphere. 2018 Mar 28;3(2). pii: e00583-17. doi: 10.1128/mSphere.00583-17. eCollection 2018 Mar-Apr.

2.

Improving chances for successful clinical outcomes with better preclinical models.

Wenzel H, Kaminski RW, Clarkson KA, Maciel M Jr, Smith MA, Zhang W, Oaks EV.

Vaccine. 2017 Dec 14;35(49 Pt A):6798-6802. doi: 10.1016/j.vaccine.2017.08.030. Epub 2017 Sep 7.

3.

Development of an Aotus nancymaae model for Shigella Vaccine immunogenicity and efficacy studies.

Gregory M, Kaminski RW, Lugo-Roman LA, Galvez Carrillo H, Tilley DH, Baldeviano C, Simons MP, Reynolds ND, Ranallo RT, Suvarnapunya AE, Venkatesan MM, Oaks EV.

Infect Immun. 2014 May;82(5):2027-36. doi: 10.1128/IAI.01665-13. Epub 2014 Mar 4.

4.

Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine.

Kaminski RW, Wu M, Turbyfill KR, Clarkson K, Tai B, Bourgeois AL, Van De Verg LL, Walker RI, Oaks EV.

Clin Vaccine Immunol. 2014 Mar;21(3):366-82. doi: 10.1128/CVI.00683-13. Epub 2014 Jan 8.

5.

Enteric pathogen surveillance in a case-control study of acute diarrhoea in the town of Kisii, Kenya.

Swierczewski BE, Odundo EA, Koech MC, Ndonye JN, Kirera RK, Odhiambo CP, Cheruiyot EK, Shaffer DN, Ombogo AN, Oaks EV.

J Med Microbiol. 2013 Nov;62(Pt 11):1774-6. doi: 10.1099/jmm.0.059139-0. Epub 2013 Jul 10. No abstract available.

PMID:
23842139
6.

Multiplexed immunoassay to assess Shigella-specific antibody responses.

Kaminski RW, Clarkson K, Kordis AA, Oaks EV.

J Immunol Methods. 2013 Jul 31;393(1-2):18-29. doi: 10.1016/j.jim.2013.04.002. Epub 2013 Apr 9.

PMID:
23583496
7.

Surveillance for enteric pathogens in a case-control study of acute diarrhea in Western Kenya.

Swierczewski BE, Odundo EA, Koech MC, Ndonye JN, Kirera RK, Odhiambo CP, Cheruiyot EK, Wu MT, Lee JE, Zhang C, Oaks EV.

Trans R Soc Trop Med Hyg. 2013 Feb;107(2):83-90. doi: 10.1093/trstmh/trs022. Epub 2012 Dec 5.

PMID:
23222955
8.

Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine.

Riddle MS, Kaminski RW, Williams C, Porter C, Baqar S, Kordis A, Gilliland T, Lapa J, Coughlin M, Soltis C, Jones E, Saunders J, Keiser PB, Ranallo RT, Gormley R, Nelson M, Turbyfill KR, Tribble D, Oaks EV.

Vaccine. 2011 Sep 16;29(40):7009-19. doi: 10.1016/j.vaccine.2011.07.033. Epub 2011 Jul 23.

PMID:
21787825
9.

Enteric disease surveillance under the AFHSC-GEIS: current efforts, landscape analysis and vision forward.

Money NN, Maves RC, Sebeny P, Kasper MR, Riddle MS; AFHSC-GEIS Enteric Surveillance Writing Group, Wu M, Lee JE, Schnabel D, Bowden R, Oaks EV, OcaƱa V, Acosta L, Gotuzzo E, Lanata C, Ochoa T, Aguayo N, Bernal M, Meza R, Canal E, Gregory M, Cepeda D, Listiyaningsih E, Putnam SD, Young S, Mansour A, Nakhla I, Moustafa M, Hassan K, Klena J, Bruton J, Shaheen H, Farid S, Fouad S, El-Mohamady H, Styles T, Shiau LC, Espinosa B, McMullen K, Reed E, Neil D, Searles D, Nevin R, Von Thun A, Sessions C.

BMC Public Health. 2011 Mar 4;11 Suppl 2:S7. doi: 10.1186/1471-2458-11-S2-S7. Review.

10.

Inactivated and subunit vaccines to prevent shigellosis.

Kaminski RW, Oaks EV.

Expert Rev Vaccines. 2009 Dec;8(12):1693-704. doi: 10.1586/erv.09.127. Review.

PMID:
19943764
11.

Genetics and virulence association of the Shigella flexneri sit iron transport system.

Fisher CR, Davies NM, Wyckoff EE, Feng Z, Oaks EV, Payne SM.

Infect Immun. 2009 May;77(5):1992-9. doi: 10.1128/IAI.00064-09. Epub 2009 Mar 16.

12.

Mucosal adjuvanticity of a Shigella invasin complex with dna-based vaccines.

Kaminski RW, Turbyfill KR, Chao C, Ching WM, Oaks EV.

Clin Vaccine Immunol. 2009 Apr;16(4):574-86. doi: 10.1128/CVI.00435-08. Epub 2009 Feb 18.

13.

Immunogenicity and efficacy of highly purified invasin complex vaccine from Shigella flexneri 2a.

Turbyfill KR, Kaminski RW, Oaks EV.

Vaccine. 2008 Mar 4;26(10):1353-64. doi: 10.1016/j.vaccine.2007.12.040. Epub 2008 Jan 17.

PMID:
18276045
14.

IpaD localizes to the tip of the type III secretion system needle of Shigella flexneri.

Espina M, Olive AJ, Kenjale R, Moore DS, Ausar SF, Kaminski RW, Oaks EV, Middaugh CR, Picking WD, Picking WL.

Infect Immun. 2006 Aug;74(8):4391-400.

15.

Mucosal adjuvant properties of the Shigella invasin complex.

Kaminski RW, Turbyfill KR, Oaks EV.

Infect Immun. 2006 May;74(5):2856-66.

16.

Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.

Oaks EV, Turbyfill KR.

Vaccine. 2006 Mar 20;24(13):2290-301. Epub 2005 Dec 5.

PMID:
16364513
17.

Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine.

Turbyfill KR, Hartman AB, Oaks EV.

Infect Immun. 2000 Dec;68(12):6624-32.

18.

Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602.

Coster TS, Hoge CW, VanDeVerg LL, Hartman AB, Oaks EV, Venkatesan MM, Cohen D, Robin G, Fontaine-Thompson A, Sansonetti PJ, Hale TL.

Infect Immun. 1999 Jul;67(7):3437-43.

19.

Identification of epitope and surface-exposed domains of Shigella flexneri invasion plasmid antigen D (IpaD).

Turbyfill KR, Mertz JA, Mallett CP, Oaks EV.

Infect Immun. 1998 May;66(5):1999-2006.

20.

Construction and characterization of virG (icsA)-deleted Escherichia coli K12-Shigella flexneri hybrid vaccine strains.

Alexander WA, Hartman AB, Oaks EV, Venkatesan MM.

Vaccine. 1996 Aug;14(11):1053-61.

PMID:
8879102
21.

Antibody response of monkeys to invasion plasmid antigen D after infection with Shigella spp.

Oaks EV, Picking WD, Picking WL.

Clin Diagn Lab Immunol. 1996 Mar;3(2):242-5.

23.

Murine T-cell response to native and recombinant protein antigens of Rickettsia tsutsugamushi.

Hickman CJ, Stover CK, Joseph SW, Oaks EV.

Infect Immun. 1993 May;61(5):1674-81.

24.
25.
26.

Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains.

Hartman AB, Powell CJ, Schultz CL, Oaks EV, Eckels KH.

Infect Immun. 1991 Nov;59(11):4075-83.

27.

Effect of prior infection with virulent Shigella flexneri 2a on the resistance of monkeys to subsequent infection with Shigella sonnei.

Formal SB, Oaks EV, Olsen RE, Wingfield-Eggleston M, Snoy PJ, Cogan JP.

J Infect Dis. 1991 Sep;164(3):533-7.

PMID:
1869840
28.

Molecular cloning and sequence analysis of a Rickettsia tsutsugamushi 22 kDa antigen containing B- and T-cell epitopes.

Hickman CJ, Stover CK, Joseph SW, Oaks EV.

Microb Pathog. 1991 Jul;11(1):19-31.

PMID:
1724548
31.

Sequence and molecular characterization of a multicopy invasion plasmid antigen gene, ipaH, of Shigella flexneri.

Hartman AB, Venkatesan M, Oaks EV, Buysse JM.

J Bacteriol. 1990 Apr;172(4):1905-15.

32.
33.

A structural and immunological comparison of rickettsial HSP60 antigens with those of other species.

Dasch GA, Ching WM, Kim PY, Pham H, Stover CK, Oaks EV, Dobson ME, Weiss E.

Ann N Y Acad Sci. 1990;590:352-69. Review. No abstract available.

PMID:
2198834
34.

Detection of Rickettsia tsutsugamushi by gene amplification using polymerase chain reaction techniques.

Kelly DJ, Marana DP, Stover CK, Oaks EV, Carl M.

Ann N Y Acad Sci. 1990;590:564-71.

PMID:
2116112
35.

Antigenic and genetic relatedness of eight Rickettsia tsutsugamushi antigens.

Oaks EV, Rice RM, Kelly DJ, Stover CK.

Infect Immun. 1989 Oct;57(10):3116-22.

36.
37.
38.

Use of conversion adaptors to clone antigen genes in lambda gt11.

Stover CK, Vodkin MH, Oaks EV.

Anal Biochem. 1987 Jun;163(2):398-407.

PMID:
2959169
39.
40.
42.

Plaque formation by virulent Shigella flexneri.

Oaks EV, Wingfield ME, Formal SB.

Infect Immun. 1985 Apr;48(1):124-9.

43.

Impairment of folic acid absorption by oral pancreatic extracts.

Russell RM, Dutta SK, Oaks EV, Rosenberg IH, Giovetti AC.

Dig Dis Sci. 1980 May;25(5):369-73.

PMID:
7371475
44.

Taxonomic relationship of vole agent to Rochalimaea quintana.

Myers WF, Wisseman CL Jr, Fiset P, Oaks EV, Smith JF.

Infect Immun. 1979 Dec;26(3):976-83.

45.

Vitamin-A reversal of abnormal dark adaptation in cirrhosis. Study of effects on the plasma retinol transport system.

Russell RM, Morrison SA, Smith FR, Oaks EV, Carney EA.

Ann Intern Med. 1978 May;88(5):622-6.

PMID:
565608
46.

Zinc deficiency: a cause of abnormal dark adaptation in cirrhotics.

Morrison SA, Russell RM, Carney EA, Oaks EV.

Am J Clin Nutr. 1978 Feb;31(2):276-81.

PMID:
623051

Supplemental Content

Support Center